Using pyrene to probe the effects of poloxamer stabilisers on internal lipid microenvironments in solid lipid nanoparticles.
Journal
Nanoscale advances
ISSN: 2516-0230
Titre abrégé: Nanoscale Adv
Pays: England
ID NLM: 101738708
Informations de publication
Date de publication:
15 Dec 2020
15 Dec 2020
Historique:
received:
16
07
2020
accepted:
10
10
2020
entrez:
22
9
2022
pubmed:
19
10
2020
medline:
19
10
2020
Statut:
epublish
Résumé
Solid lipid nanoparticles (SLNs) have proved to be effective nanocarriers with many advantages over other non-lipid-based systems. The development of new SLN formulations is often hindered through poor drug loading capacity and time-consuming optimisation of lipid/stabiliser combinations. One challenge in the development of new SLN formulations is understanding the complex interactions between amphiphilic stabilisers and hydrophobic lipids; the nature of these interactions can significantly impact SLN properties, including the internal polarity within the nanoparticle core. Herein, we report the use of pyrene to probe the internal lipid microenvironment inside SLNs. We investigate the effect of using different poloxamer stabilisers on the internal polarity of SLNs formed using the common solid lipid, Compritol 888 ATO. We show that the polarity of the internal lipid environment is modified by the length of the poly(propylene oxide) (PPO) block of the poloxamer stabiliser, with longer PPO blocks producing SLNs with less polar lipid cores. Blending of stabilisers could also be used to tune the polarity of the core lipid environment, which may allow for adjusting the polarity of the lipid to assist the loading of different therapeutics.
Identifiants
pubmed: 36133871
doi: 10.1039/d0na00582g
pii: d0na00582g
pmc: PMC9417865
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5572-5577Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Indian J Pharm Sci. 2009 Jul;71(4):349-58
pubmed: 20502539
Daru. 2015 Sep 21;23:46
pubmed: 26392174
J Funct Biomater. 2018 Jan 18;9(1):
pubmed: 29346330
Colloids Surf B Biointerfaces. 2012 Jun 1;94:68-72
pubmed: 22326649
Anticancer Agents Med Chem. 2012 Dec;12(10):1264-80
pubmed: 22583407
Mater Sci Eng C Mater Biol Appl. 2013 May 1;33(4):1842-52
pubmed: 23498204
Colloids Surf B Biointerfaces. 2010 Aug 1;79(1):254-61
pubmed: 20447810
Acta Pharm Sin B. 2014 Dec;4(6):454-63
pubmed: 26579417
J Ocul Pharmacol Ther. 2013 Mar;29(2):216-28
pubmed: 23421502
Pharm Dev Technol. 2019 Dec;24(10):1287-1298
pubmed: 31507232
J Microencapsul. 2006 Jun;23(4):417-33
pubmed: 16854817
Res Pharm Sci. 2018 Aug;13(4):288-303
pubmed: 30065762
J Agric Food Chem. 2005 Jun 1;53(11):4355-60
pubmed: 15913295
Mol Pharm. 2016 Aug 1;13(8):2667-76
pubmed: 27379550
Eur J Pharm Biopharm. 2003 Jan;55(1):125-31
pubmed: 12551713
Pharmaceutics. 2019 Mar 19;11(3):
pubmed: 30893859
Biochemistry. 2012 Aug 7;51(31):6207-19
pubmed: 22779734
Carbohydr Polym. 2015 May 20;122:221-9
pubmed: 25817662
J Cell Biochem. 2018 Jun;119(6):4251-4264
pubmed: 29243841
Curr Drug Discov Technol. 2012 Mar;9(1):2-16
pubmed: 22235925
Int J Nanomedicine. 2007;2(3):289-300
pubmed: 18019829
Biomed Res Int. 2013;2013:410686
pubmed: 23984361
Pharmaceutics. 2018 Oct 18;10(4):
pubmed: 30340327
Int J Nanomedicine. 2017 May 31;12:4085-4109
pubmed: 28615938
ACS Omega. 2019 Aug 07;4(8):13360-13370
pubmed: 31460464
Nanomaterials (Basel). 2018 Dec 27;9(1):
pubmed: 30591688
Cell Biol Int. 2019 Jan;43(1):2-11
pubmed: 30080277
Expert Opin Drug Deliv. 2014 Dec;11(12):1865-83
pubmed: 25152197
Front Pharmacol. 2016 Sep 21;7:332
pubmed: 27708583
Colloids Surf B Biointerfaces. 2008 Feb 15;61(2):132-7
pubmed: 17888636
Acta Pharm. 2012 Dec;62(4):433-72
pubmed: 23333884